Viridian Therapeutics (VRDN)
16.57
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 8-K Viridian Therapeutics, For: Jun 02
June 3, 2026 7:00 AM - SEC Filing
Morgan Stanley: China healthcare sector dips 1.3% amid licensing scrutiny
May 29, 2026 12:07 PM - StreetInsider
Form 8-K Viridian Therapeutics, For: May 27
May 28, 2026 4:49 PM - SEC Filing
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
May 27, 2026 7:00 AM - BizWire
Form 8-K Viridian Therapeutics, For: May 24
May 26, 2026 4:13 PM - SEC Filing
Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project
May 19, 2026 1:30 PM - Globe NewsWire
Form SCHEDULE 13G Viridian Therapeutics, Filed by: Bellevue Group AG
May 15, 2026 2:38 PM - SEC Filing
Viridian Therapeutic (VRDN) PT Lowered to $26 at Evercore ISI
May 15, 2026 7:15 AM - StreetInsider
Form 4 Viridian Therapeutics, For: May 11 Filed by: Fairmount Healthcare Fund II GP LLC
May 13, 2026 4:31 PM - SEC Filing
Form SCHEDULE 13D/A Viridian Therapeutics, Filed by: Fairmount Funds Management LLC
May 13, 2026 4:31 PM - SEC Filing
Viridian Therapeutic (VRDN) PT Lowered to $39 at Stifel
May 13, 2026 10:12 AM - StreetInsider
Form 8-K Viridian Therapeutics, For: May 06
May 11, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G Viridian Therapeutics, Filed by: Deep Track Capital, LP
May 8, 2026 4:18 PM - SEC Filing
Form 424B5 Viridian Therapeutics,
May 8, 2026 4:07 PM - SEC Filing
Form 424B5 Viridian Therapeutics,
May 8, 2026 4:06 PM - SEC Filing
Form FWP Viridian Therapeutics, Filed by: Viridian Therapeutics, Inc.\DE
May 7, 2026 6:09 AM - SEC Filing
Form FWP Viridian Therapeutics, Filed by: Viridian Therapeutics, Inc.\DE
May 7, 2026 6:09 AM - SEC Filing
Form 305B2 Viridian Therapeutics,
May 7, 2026 6:08 AM - SEC Filing
Viridian Therapeutics prices $350 million dual offering with notes and stock
May 6, 2026 11:13 PM - StreetInsider
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
May 6, 2026 11:13 PM - BizWire
Viridian Therapeutic (VRDN) PT Raised to $35 at Truist Securities
May 6, 2026 7:12 AM - StreetInsider
Form 424B5 Viridian Therapeutics,
May 6, 2026 6:07 AM - SEC Filing
Form 424B5 Viridian Therapeutics,
May 6, 2026 6:07 AM - SEC Filing
Viridian Therapeutic (VRDN) PT Raised to $34 at RBC Capital
May 6, 2026 4:20 AM - StreetInsider
Form FWP Viridian Therapeutics, Filed by: Viridian Therapeutics, Inc.\DE
May 5, 2026 5:19 PM - SEC Filing
Viridian Therapeutics announces $250 million in proposed public offerings
May 5, 2026 4:05 PM - StreetInsider
Viridian Therapeutics launches $250 million dual public offering
May 5, 2026 4:05 PM - StreetInsider
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
May 5, 2026 4:05 PM - BizWire
Viridian Therapeutic (VRDN) PT Raised to $28 at Jefferies
May 5, 2026 12:24 PM - StreetInsider
Form 8-K Viridian Therapeutics, For: May 05
May 5, 2026 7:57 AM - SEC Filing
Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 99c
May 5, 2026 7:31 AM - StreetInsider
Form 10-Q Viridian Therapeutics, For: Mar 31
May 5, 2026 7:06 AM - SEC Filing
Form 8-K Viridian Therapeutics, For: May 05
May 5, 2026 7:05 AM - SEC Filing
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
May 5, 2026 7:01 AM - BizWire
Viridian reports positive Phase 3 results for chronic thyroid eye disease drug
May 5, 2026 7:00 AM - StreetInsider
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
May 5, 2026 7:00 AM - BizWire
Viridian Therapeutic (VRDN) PT Lowered to $33 at Truist Securities
April 21, 2026 8:50 AM - StreetInsider
Form ARS Viridian Therapeutics, For: Dec 31
April 17, 2026 8:06 AM - SEC Filing
Form DEFA14A Viridian Therapeutics,
April 17, 2026 8:03 AM - SEC Filing
Form DEF 14A Viridian Therapeutics, For: Jun 02
April 17, 2026 8:01 AM - SEC Filing
Viridian Announces Market Services Agreement With Outside The Box Capital
April 15, 2026 6:29 PM - Globe NewsWire
Viridian Therapeutic (VRDN) PT Lowered to $24 at Evercore ISI
April 13, 2026 10:11 AM - StreetInsider
Viridian Metals Secures $225,000 Maximum JEA Funding; Adopts Quarterly Reporting Exemption
April 8, 2026 2:00 PM - Globe NewsWire
Viridian Therapeutic (VRDN) PT Lowered to $36 at Truist Securities
April 8, 2026 6:06 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
April 7, 2026 7:49 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Lowered to $30 at RBC Capital
April 7, 2026 5:44 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Lowered to $31 at Goldman Sachs
April 6, 2026 6:01 PM - StreetInsider
Leerink Partners on Viridian Therapeutic (VRDN): share weakness on AMGN results 'overdone'
April 6, 2026 1:12 PM - StreetInsider
RBC: 'we expect to see a negative impact to VRDN's shares', Shares 24% Today
April 6, 2026 11:45 AM - StreetInsider
Stifel on Viridian (VRDN): 'We view positive REVEAL-2 chronic TED data in 2Q26 as important'
April 6, 2026 9:46 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Lowered to $32 at Evercore ISI
April 2, 2026 5:14 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Lowered to $20 at Wells Fargo
March 31, 2026 6:49 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Lowered to $22 at H.C. Wainwright
March 31, 2026 6:38 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Lowered to $36 at Goldman Sachs
March 31, 2026 6:24 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Lowered to $29 at Wolfe Research
March 31, 2026 5:34 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Lowered to $29 at Jefferies
March 30, 2026 1:02 PM - StreetInsider
Stifel on Viridian Therapeutic (VRDN): data 'disappointing at face,' but Elegrobart still potentially BIC
March 30, 2026 9:19 AM - StreetInsider
Truist Securities on Viridian Therapeutic (VRDN): data places SC Ele' as 'notable therapeutic companion' to IV Veli'
March 30, 2026 8:46 AM - StreetInsider
Leerink Partners on Viridian Therapeutic (VRDN): 'encouraged' by response rate, but efficacy below investor expectations
March 30, 2026 8:41 AM - StreetInsider
Jefferies on Viridian Therapeutic (VRDN): bears to argue commercial oppy not clean, bulls see de-risk
March 30, 2026 8:24 AM - StreetInsider
Form 8-K Viridian Therapeutics, For: Mar 30
March 30, 2026 7:51 AM - SEC Filing
Viridian says elegrobart meets primary goal in thyroid eye disease trial
March 30, 2026 7:02 AM - StreetInsider
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
March 30, 2026 7:01 AM - BizWire
Form SCHEDULE 13G/A Viridian Therapeutics, Filed by: VANGUARD GROUP INC
March 27, 2026 1:55 PM - SEC Filing
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Form 4/A Viridian Therapeutics, For: Mar 03 Filed by: Harmon Seth
March 9, 2026 7:50 PM - SEC Filing
Form 4/A Viridian Therapeutics, For: Mar 03 Filed by: Beetham Thomas W.
March 9, 2026 7:43 PM - SEC Filing
Form 4/A Viridian Therapeutics, For: Mar 03 Filed by: Tousignant Jennifer
March 9, 2026 7:35 PM - SEC Filing
Form 4/A Viridian Therapeutics, For: Mar 03 Filed by: Mahoney Stephen F.
March 9, 2026 7:35 PM - SEC Filing
Full Article List
